Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLC Article Swipe
Mengni Guo
,
Won Jin Jeon
,
B Joung
,
Derek Tai
,
Alexander Gavralidis
,
Andrew Elliott
,
Yasmine Baca
,
David de Semir
,
Stephen V. Liu
,
Mark E. Reeves
,
Saied Mirshahidi
,
Hamid Mirshahidi
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/cancers17172895
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3390/cancers17172895
Purpose: Preclinical studies suggest that interleukin-1β (IL-1β) influences tumor behavior in non-small cell lung cancer (NSCLC). While the CANTOS trial demonstrated reduced lung cancer incidence with IL-1β inhibition, the CANOPY trials failed to show survival benefit when combined with chemoimmunotherapy. The role of IL-1β in NSCLC with oncogenic mutations remains unclear. We evaluated the prognostic and predictive significance of IL-1β expression across NSCLC subtypes. Methods: We analyzed 21,698 NSCLC tumors profiled by Caris Life Sciences using DNA and RNA next-generation sequencing. IL-1β expression was stratified into quartiles (Q1: lowest 25%, Q4: highest 25%). Real-world overall survival (OS) and time on treatment (TOT) were obtained from insurance claims. Statistical comparisons used Chi-square, Fisher’s exact, or Mann–Whitney U tests. Survival outcomes were assessed with Cox models. Results: Across unselected NSCLC patients, low IL-1β expression (Q1) was associated with modestly longer OS versus high expression (Q4) (median OS 19.5 vs. 17.4 months; HR 0.94; p < 0.0001). This effect was more pronounced in EGFR-mutant adenocarcinoma (36.7 vs. 27.2 months; HR 0.76; p < 0.001) and ALK fusion-positive NSCLC (53.0 vs. 35.2 months; HR 0.62; p = 0.002). In NSCLC without targetable mutations, IL-1β expression was not prognostic. In KRAS-mutant adenocarcinoma, high IL-1β expression was associated with modestly longer TOT on immunotherapy (7.4 vs. 6.4 months; HR 1.15; p = 0.041), but not OS. High IL-1β expression correlated positively with TP53 mutation, TMB-high, and PD-L1 expression and inversely with EGFR, KRAS, BRAF, ERBB2, KEAP1, and STK11 mutations. Conclusions: IL-1β expression is a potential prognostic and predictive biomarker in NSCLC, associated with survival outcomes in defined molecular subsets. These findings suggest that IL-1β-targeted strategies may be particularly relevant in EGFR- or ALK-altered tumors.
Related Topics
Concepts
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3390/cancers17172895
- https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394
- OA Status
- gold
- Cited By
- 1
- References
- 46
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W4413948658
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4413948658Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3390/cancers17172895Digital Object Identifier
- Title
-
Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLCWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-03Full publication date if available
- Authors
-
Mengni Guo, Won Jin Jeon, B Joung, Derek Tai, Alexander Gavralidis, Andrew Elliott, Yasmine Baca, David de Semir, Stephen V. Liu, Mark E. Reeves, Saied Mirshahidi, Hamid MirshahidiList of authors in order
- Landing page
-
https://doi.org/10.3390/cancers17172895Publisher landing page
- PDF URL
-
https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394Direct link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394Direct OA link when available
- Concepts
-
Cancer research, Oncogene, Interleukin, Medicine, Oncology, Internal medicine, Computational biology, Biology, Cancer, Cytokine, Cell cycleTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
46Number of works referenced by this work
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W4413948658 |
|---|---|
| doi | https://doi.org/10.3390/cancers17172895 |
| ids.doi | https://doi.org/10.3390/cancers17172895 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40940992 |
| ids.openalex | https://openalex.org/W4413948658 |
| fwci | 3.27053909 |
| type | article |
| title | Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLC |
| biblio.issue | 17 |
| biblio.volume | 17 |
| biblio.last_page | 2895 |
| biblio.first_page | 2895 |
| topics[0].id | https://openalex.org/T10158 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9991999864578247 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2730 |
| topics[0].subfield.display_name | Oncology |
| topics[0].display_name | Cancer Immunotherapy and Biomarkers |
| topics[1].id | https://openalex.org/T11503 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9991000294685364 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2730 |
| topics[1].subfield.display_name | Oncology |
| topics[1].display_name | Cytokine Signaling Pathways and Interactions |
| topics[2].id | https://openalex.org/T11532 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9970999956130981 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2730 |
| topics[2].subfield.display_name | Oncology |
| topics[2].display_name | Chemokine receptors and signaling |
| is_xpac | False |
| apc_list.value | 2400 |
| apc_list.currency | CHF |
| apc_list.value_usd | 2598 |
| apc_paid.value | 2400 |
| apc_paid.currency | CHF |
| apc_paid.value_usd | 2598 |
| concepts[0].id | https://openalex.org/C502942594 |
| concepts[0].level | 1 |
| concepts[0].score | 0.49673205614089966 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q3421914 |
| concepts[0].display_name | Cancer research |
| concepts[1].id | https://openalex.org/C2781018059 |
| concepts[1].level | 4 |
| concepts[1].score | 0.4807679355144501 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q207609 |
| concepts[1].display_name | Oncogene |
| concepts[2].id | https://openalex.org/C74172505 |
| concepts[2].level | 3 |
| concepts[2].score | 0.4525548219680786 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q194908 |
| concepts[2].display_name | Interleukin |
| concepts[3].id | https://openalex.org/C71924100 |
| concepts[3].level | 0 |
| concepts[3].score | 0.4363935589790344 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[3].display_name | Medicine |
| concepts[4].id | https://openalex.org/C143998085 |
| concepts[4].level | 1 |
| concepts[4].score | 0.41043779253959656 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q162555 |
| concepts[4].display_name | Oncology |
| concepts[5].id | https://openalex.org/C126322002 |
| concepts[5].level | 1 |
| concepts[5].score | 0.3570793867111206 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q11180 |
| concepts[5].display_name | Internal medicine |
| concepts[6].id | https://openalex.org/C70721500 |
| concepts[6].level | 1 |
| concepts[6].score | 0.3442085385322571 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q177005 |
| concepts[6].display_name | Computational biology |
| concepts[7].id | https://openalex.org/C86803240 |
| concepts[7].level | 0 |
| concepts[7].score | 0.32851642370224 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[7].display_name | Biology |
| concepts[8].id | https://openalex.org/C121608353 |
| concepts[8].level | 2 |
| concepts[8].score | 0.1918962299823761 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q12078 |
| concepts[8].display_name | Cancer |
| concepts[9].id | https://openalex.org/C2778690821 |
| concepts[9].level | 2 |
| concepts[9].score | 0.17053967714309692 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q212354 |
| concepts[9].display_name | Cytokine |
| concepts[10].id | https://openalex.org/C29537977 |
| concepts[10].level | 3 |
| concepts[10].score | 0.09902569651603699 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q188941 |
| concepts[10].display_name | Cell cycle |
| keywords[0].id | https://openalex.org/keywords/cancer-research |
| keywords[0].score | 0.49673205614089966 |
| keywords[0].display_name | Cancer research |
| keywords[1].id | https://openalex.org/keywords/oncogene |
| keywords[1].score | 0.4807679355144501 |
| keywords[1].display_name | Oncogene |
| keywords[2].id | https://openalex.org/keywords/interleukin |
| keywords[2].score | 0.4525548219680786 |
| keywords[2].display_name | Interleukin |
| keywords[3].id | https://openalex.org/keywords/medicine |
| keywords[3].score | 0.4363935589790344 |
| keywords[3].display_name | Medicine |
| keywords[4].id | https://openalex.org/keywords/oncology |
| keywords[4].score | 0.41043779253959656 |
| keywords[4].display_name | Oncology |
| keywords[5].id | https://openalex.org/keywords/internal-medicine |
| keywords[5].score | 0.3570793867111206 |
| keywords[5].display_name | Internal medicine |
| keywords[6].id | https://openalex.org/keywords/computational-biology |
| keywords[6].score | 0.3442085385322571 |
| keywords[6].display_name | Computational biology |
| keywords[7].id | https://openalex.org/keywords/biology |
| keywords[7].score | 0.32851642370224 |
| keywords[7].display_name | Biology |
| keywords[8].id | https://openalex.org/keywords/cancer |
| keywords[8].score | 0.1918962299823761 |
| keywords[8].display_name | Cancer |
| keywords[9].id | https://openalex.org/keywords/cytokine |
| keywords[9].score | 0.17053967714309692 |
| keywords[9].display_name | Cytokine |
| keywords[10].id | https://openalex.org/keywords/cell-cycle |
| keywords[10].score | 0.09902569651603699 |
| keywords[10].display_name | Cell cycle |
| language | en |
| locations[0].id | doi:10.3390/cancers17172895 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S168415115 |
| locations[0].source.issn | 2072-6694 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2072-6694 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | False |
| locations[0].source.display_name | Cancers |
| locations[0].source.host_organization | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310310987 |
| locations[0].source.host_organization_lineage_names | Multidisciplinary Digital Publishing Institute |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394 |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Cancers |
| locations[0].landing_page_url | https://doi.org/10.3390/cancers17172895 |
| locations[1].id | pmid:40940992 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Cancers |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40940992 |
| indexed_in | crossref, pubmed |
| authorships[0].author.id | https://openalex.org/A5041138991 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-2978-8607 |
| authorships[0].author.display_name | Mengni Guo |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[0].affiliations[0].raw_affiliation_string | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[0].institutions[0].id | https://openalex.org/I26347476 |
| authorships[0].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[0].institutions[0].type | education |
| authorships[0].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | Loma Linda University |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Mengni Guo |
| authorships[0].is_corresponding | False |
| authorships[0].raw_affiliation_strings | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[1].author.id | https://openalex.org/A5052756076 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-5212-5284 |
| authorships[1].author.display_name | Won Jin Jeon |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[1].affiliations[0].raw_affiliation_string | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[1].institutions[0].id | https://openalex.org/I26347476 |
| authorships[1].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[1].institutions[0].type | education |
| authorships[1].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | Loma Linda University |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Won Jin Jeon |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[2].author.id | https://openalex.org/A5082913529 |
| authorships[2].author.orcid | https://orcid.org/0009-0000-9797-4511 |
| authorships[2].author.display_name | B Joung |
| authorships[2].countries | US |
| authorships[2].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[2].affiliations[0].raw_affiliation_string | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[2].institutions[0].id | https://openalex.org/I26347476 |
| authorships[2].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[2].institutions[0].type | education |
| authorships[2].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[2].institutions[0].country_code | US |
| authorships[2].institutions[0].display_name | Loma Linda University |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Bowon Joung |
| authorships[2].is_corresponding | False |
| authorships[2].raw_affiliation_strings | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[3].author.id | https://openalex.org/A5070744695 |
| authorships[3].author.orcid | https://orcid.org/0000-0002-6461-5560 |
| authorships[3].author.display_name | Derek Tai |
| authorships[3].countries | US |
| authorships[3].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[3].affiliations[0].raw_affiliation_string | Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[3].institutions[0].id | https://openalex.org/I26347476 |
| authorships[3].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[3].institutions[0].type | education |
| authorships[3].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[3].institutions[0].country_code | US |
| authorships[3].institutions[0].display_name | Loma Linda University |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Derek Tai |
| authorships[3].is_corresponding | False |
| authorships[3].raw_affiliation_strings | Department of Internal Medicine, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[4].author.id | https://openalex.org/A5077057876 |
| authorships[4].author.orcid | |
| authorships[4].author.display_name | Alexander Gavralidis |
| authorships[4].countries | US |
| authorships[4].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[4].affiliations[0].raw_affiliation_string | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[4].institutions[0].id | https://openalex.org/I26347476 |
| authorships[4].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[4].institutions[0].type | education |
| authorships[4].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[4].institutions[0].country_code | US |
| authorships[4].institutions[0].display_name | Loma Linda University |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Alexander Gavralidis |
| authorships[4].is_corresponding | False |
| authorships[4].raw_affiliation_strings | Division of Hematology and Oncology, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[5].author.id | https://openalex.org/A5029537789 |
| authorships[5].author.orcid | https://orcid.org/0000-0001-8494-8031 |
| authorships[5].author.display_name | Andrew Elliott |
| authorships[5].countries | US |
| authorships[5].affiliations[0].institution_ids | https://openalex.org/I4210140103 |
| authorships[5].affiliations[0].raw_affiliation_string | Caris Life Sciences Inc., Phoenix, AZ 85040, USA |
| authorships[5].institutions[0].id | https://openalex.org/I4210140103 |
| authorships[5].institutions[0].ror | https://ror.org/04wh5hg83 |
| authorships[5].institutions[0].type | company |
| authorships[5].institutions[0].lineage | https://openalex.org/I4210140103 |
| authorships[5].institutions[0].country_code | US |
| authorships[5].institutions[0].display_name | Caris Life Sciences (United States) |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Andrew Elliott |
| authorships[5].is_corresponding | False |
| authorships[5].raw_affiliation_strings | Caris Life Sciences Inc., Phoenix, AZ 85040, USA |
| authorships[6].author.id | https://openalex.org/A5071826146 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-2130-0611 |
| authorships[6].author.display_name | Yasmine Baca |
| authorships[6].countries | US |
| authorships[6].affiliations[0].institution_ids | https://openalex.org/I4210140103 |
| authorships[6].affiliations[0].raw_affiliation_string | Caris Life Sciences Inc., Phoenix, AZ 85040, USA |
| authorships[6].institutions[0].id | https://openalex.org/I4210140103 |
| authorships[6].institutions[0].ror | https://ror.org/04wh5hg83 |
| authorships[6].institutions[0].type | company |
| authorships[6].institutions[0].lineage | https://openalex.org/I4210140103 |
| authorships[6].institutions[0].country_code | US |
| authorships[6].institutions[0].display_name | Caris Life Sciences (United States) |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Yasmine Baca |
| authorships[6].is_corresponding | False |
| authorships[6].raw_affiliation_strings | Caris Life Sciences Inc., Phoenix, AZ 85040, USA |
| authorships[7].author.id | https://openalex.org/A5053789515 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8250-2183 |
| authorships[7].author.display_name | David de Semir |
| authorships[7].countries | US |
| authorships[7].affiliations[0].institution_ids | https://openalex.org/I4210140103 |
| authorships[7].affiliations[0].raw_affiliation_string | Caris Life Sciences Inc., Phoenix, AZ 85040, USA |
| authorships[7].institutions[0].id | https://openalex.org/I4210140103 |
| authorships[7].institutions[0].ror | https://ror.org/04wh5hg83 |
| authorships[7].institutions[0].type | company |
| authorships[7].institutions[0].lineage | https://openalex.org/I4210140103 |
| authorships[7].institutions[0].country_code | US |
| authorships[7].institutions[0].display_name | Caris Life Sciences (United States) |
| authorships[7].author_position | middle |
| authorships[7].raw_author_name | David de Semir |
| authorships[7].is_corresponding | False |
| authorships[7].raw_affiliation_strings | Caris Life Sciences Inc., Phoenix, AZ 85040, USA |
| authorships[8].author.id | https://openalex.org/A5043871151 |
| authorships[8].author.orcid | https://orcid.org/0000-0002-4852-3914 |
| authorships[8].author.display_name | Stephen V. Liu |
| authorships[8].countries | US |
| authorships[8].affiliations[0].institution_ids | https://openalex.org/I184565670, https://openalex.org/I2799903593 |
| authorships[8].affiliations[0].raw_affiliation_string | Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA |
| authorships[8].institutions[0].id | https://openalex.org/I184565670 |
| authorships[8].institutions[0].ror | https://ror.org/05vzafd60 |
| authorships[8].institutions[0].type | education |
| authorships[8].institutions[0].lineage | https://openalex.org/I184565670 |
| authorships[8].institutions[0].country_code | US |
| authorships[8].institutions[0].display_name | Georgetown University |
| authorships[8].institutions[1].id | https://openalex.org/I2799903593 |
| authorships[8].institutions[1].ror | https://ror.org/00hjz7x27 |
| authorships[8].institutions[1].type | healthcare |
| authorships[8].institutions[1].lineage | https://openalex.org/I2799903593 |
| authorships[8].institutions[1].country_code | US |
| authorships[8].institutions[1].display_name | Georgetown University Medical Center |
| authorships[8].author_position | middle |
| authorships[8].raw_author_name | Stephen V. Liu |
| authorships[8].is_corresponding | False |
| authorships[8].raw_affiliation_strings | Lombardi Comprehensive Cancer Center, Georgetown University, Washington, DC 20007, USA |
| authorships[9].author.id | https://openalex.org/A5005427020 |
| authorships[9].author.orcid | https://orcid.org/0009-0001-1091-0177 |
| authorships[9].author.display_name | Mark E. Reeves |
| authorships[9].countries | US |
| authorships[9].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[9].affiliations[0].raw_affiliation_string | Loma Linda University Cancer Center, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[9].institutions[0].id | https://openalex.org/I26347476 |
| authorships[9].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[9].institutions[0].type | education |
| authorships[9].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[9].institutions[0].country_code | US |
| authorships[9].institutions[0].display_name | Loma Linda University |
| authorships[9].author_position | middle |
| authorships[9].raw_author_name | Mark Reeves |
| authorships[9].is_corresponding | False |
| authorships[9].raw_affiliation_strings | Loma Linda University Cancer Center, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[10].author.id | https://openalex.org/A5007644298 |
| authorships[10].author.orcid | https://orcid.org/0000-0003-1747-8070 |
| authorships[10].author.display_name | Saied Mirshahidi |
| authorships[10].countries | US |
| authorships[10].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[10].affiliations[0].raw_affiliation_string | Biospecimen Laboratory, Department of Medicine and Basic Sciences, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[10].institutions[0].id | https://openalex.org/I26347476 |
| authorships[10].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[10].institutions[0].type | education |
| authorships[10].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[10].institutions[0].country_code | US |
| authorships[10].institutions[0].display_name | Loma Linda University |
| authorships[10].author_position | middle |
| authorships[10].raw_author_name | Saied Mirshahidi |
| authorships[10].is_corresponding | False |
| authorships[10].raw_affiliation_strings | Biospecimen Laboratory, Department of Medicine and Basic Sciences, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[11].author.id | https://openalex.org/A5066525575 |
| authorships[11].author.orcid | https://orcid.org/0000-0002-7911-7118 |
| authorships[11].author.display_name | Hamid Mirshahidi |
| authorships[11].countries | US |
| authorships[11].affiliations[0].institution_ids | https://openalex.org/I26347476 |
| authorships[11].affiliations[0].raw_affiliation_string | Loma Linda University Cancer Center, Loma Linda University, Loma Linda, CA 92354, USA |
| authorships[11].institutions[0].id | https://openalex.org/I26347476 |
| authorships[11].institutions[0].ror | https://ror.org/04bj28v14 |
| authorships[11].institutions[0].type | education |
| authorships[11].institutions[0].lineage | https://openalex.org/I26347476 |
| authorships[11].institutions[0].country_code | US |
| authorships[11].institutions[0].display_name | Loma Linda University |
| authorships[11].author_position | last |
| authorships[11].raw_author_name | Hamid Mirshahidi |
| authorships[11].is_corresponding | True |
| authorships[11].raw_affiliation_strings | Loma Linda University Cancer Center, Loma Linda University, Loma Linda, CA 92354, USA |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Prognostic Significance and Emerging Predictive Potential of Interleukin-1β Expression in Oncogene-Driven NSCLC |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10158 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9991999864578247 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2730 |
| primary_topic.subfield.display_name | Oncology |
| primary_topic.display_name | Cancer Immunotherapy and Biomarkers |
| related_works | https://openalex.org/W2050014257, https://openalex.org/W2967566052, https://openalex.org/W1990949341, https://openalex.org/W2409888422, https://openalex.org/W2152682783, https://openalex.org/W2013973825, https://openalex.org/W2064378035, https://openalex.org/W2955113018, https://openalex.org/W2802381746, https://openalex.org/W2580029392 |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 2 |
| best_oa_location.id | doi:10.3390/cancers17172895 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S168415115 |
| best_oa_location.source.issn | 2072-6694 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2072-6694 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | False |
| best_oa_location.source.display_name | Cancers |
| best_oa_location.source.host_organization | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| best_oa_location.source.host_organization_lineage_names | Multidisciplinary Digital Publishing Institute |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394 |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Cancers |
| best_oa_location.landing_page_url | https://doi.org/10.3390/cancers17172895 |
| primary_location.id | doi:10.3390/cancers17172895 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S168415115 |
| primary_location.source.issn | 2072-6694 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2072-6694 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | False |
| primary_location.source.display_name | Cancers |
| primary_location.source.host_organization | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_name | Multidisciplinary Digital Publishing Institute |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310310987 |
| primary_location.source.host_organization_lineage_names | Multidisciplinary Digital Publishing Institute |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.mdpi.com/2072-6694/17/17/2895/pdf?version=1756897394 |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Cancers |
| primary_location.landing_page_url | https://doi.org/10.3390/cancers17172895 |
| publication_date | 2025-09-03 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2784371446, https://openalex.org/W3075660836, https://openalex.org/W3165585845, https://openalex.org/W2883276763, https://openalex.org/W1999406693, https://openalex.org/W2004447523, https://openalex.org/W2902538632, https://openalex.org/W2774856823, https://openalex.org/W2083084591, https://openalex.org/W3039671381, https://openalex.org/W2267049176, https://openalex.org/W2017316655, https://openalex.org/W2120929800, https://openalex.org/W2140109386, https://openalex.org/W2118278569, https://openalex.org/W2021857124, https://openalex.org/W2143662246, https://openalex.org/W2548970662, https://openalex.org/W3029987135, https://openalex.org/W2807835852, https://openalex.org/W2987791246, https://openalex.org/W4387310519, https://openalex.org/W4390933709, https://openalex.org/W4389243374, https://openalex.org/W3083986479, https://openalex.org/W2947554843, https://openalex.org/W4384695587, https://openalex.org/W2117692326, https://openalex.org/W2123105952, https://openalex.org/W1965037168, https://openalex.org/W2748400555, https://openalex.org/W2750254726, https://openalex.org/W4310753427, https://openalex.org/W4297984664, https://openalex.org/W4293033848, https://openalex.org/W2058454017, https://openalex.org/W4364380738, https://openalex.org/W4210760577, https://openalex.org/W3014509583, https://openalex.org/W3009846579, https://openalex.org/W2272547721, https://openalex.org/W1987912339, https://openalex.org/W4382243991, https://openalex.org/W4388828410, https://openalex.org/W1960216149, https://openalex.org/W4399480529 |
| referenced_works_count | 46 |
| abstract_inverted_index.= | 182, 215 |
| abstract_inverted_index.U | 115 |
| abstract_inverted_index.a | 247 |
| abstract_inverted_index.p | 151, 168, 181, 214 |
| abstract_inverted_index.HR | 149, 166, 179, 212 |
| abstract_inverted_index.In | 184, 194 |
| abstract_inverted_index.OS | 138, 144 |
| abstract_inverted_index.We | 51, 65 |
| abstract_inverted_index.be | 270 |
| abstract_inverted_index.by | 71 |
| abstract_inverted_index.in | 10, 44, 159, 253, 259, 273 |
| abstract_inverted_index.is | 246 |
| abstract_inverted_index.of | 42, 58 |
| abstract_inverted_index.on | 99, 206 |
| abstract_inverted_index.or | 113, 275 |
| abstract_inverted_index.to | 32 |
| abstract_inverted_index.6.4 | 210 |
| abstract_inverted_index.ALK | 172 |
| abstract_inverted_index.Cox | 122 |
| abstract_inverted_index.DNA | 76 |
| abstract_inverted_index.OS. | 219 |
| abstract_inverted_index.Q4: | 90 |
| abstract_inverted_index.RNA | 78 |
| abstract_inverted_index.TOT | 205 |
| abstract_inverted_index.The | 40 |
| abstract_inverted_index.and | 55, 77, 97, 171, 229, 232, 240, 250 |
| abstract_inverted_index.but | 217 |
| abstract_inverted_index.low | 129 |
| abstract_inverted_index.may | 269 |
| abstract_inverted_index.not | 192, 218 |
| abstract_inverted_index.the | 17, 28, 53 |
| abstract_inverted_index.vs. | 146, 163, 176, 209 |
| abstract_inverted_index.was | 83, 133, 156, 191, 200 |
| abstract_inverted_index.< | 152, 169 |
| abstract_inverted_index.(7.4 | 208 |
| abstract_inverted_index.(OS) | 96 |
| abstract_inverted_index.(Q1) | 132 |
| abstract_inverted_index.(Q1: | 87 |
| abstract_inverted_index.(Q4) | 142 |
| abstract_inverted_index.17.4 | 147 |
| abstract_inverted_index.19.5 | 145 |
| abstract_inverted_index.25%, | 89 |
| abstract_inverted_index.27.2 | 164 |
| abstract_inverted_index.35.2 | 177 |
| abstract_inverted_index.High | 220 |
| abstract_inverted_index.Life | 73 |
| abstract_inverted_index.TP53 | 226 |
| abstract_inverted_index.This | 154 |
| abstract_inverted_index.cell | 12 |
| abstract_inverted_index.from | 104 |
| abstract_inverted_index.high | 140, 197 |
| abstract_inverted_index.into | 85 |
| abstract_inverted_index.lung | 13, 22 |
| abstract_inverted_index.more | 157 |
| abstract_inverted_index.role | 41 |
| abstract_inverted_index.show | 33 |
| abstract_inverted_index.that | 4, 266 |
| abstract_inverted_index.time | 98 |
| abstract_inverted_index.used | 109 |
| abstract_inverted_index.were | 102, 119 |
| abstract_inverted_index.when | 36 |
| abstract_inverted_index.with | 25, 38, 46, 121, 135, 202, 225, 234, 256 |
| abstract_inverted_index.(36.7 | 162 |
| abstract_inverted_index.(53.0 | 175 |
| abstract_inverted_index.(TOT) | 101 |
| abstract_inverted_index.0.62; | 180 |
| abstract_inverted_index.0.76; | 167 |
| abstract_inverted_index.0.94; | 150 |
| abstract_inverted_index.1.15; | 213 |
| abstract_inverted_index.25%). | 92 |
| abstract_inverted_index.BRAF, | 237 |
| abstract_inverted_index.Caris | 72 |
| abstract_inverted_index.EGFR, | 235 |
| abstract_inverted_index.EGFR- | 274 |
| abstract_inverted_index.KRAS, | 236 |
| abstract_inverted_index.NSCLC | 45, 62, 68, 127, 174, 185 |
| abstract_inverted_index.PD-L1 | 230 |
| abstract_inverted_index.STK11 | 241 |
| abstract_inverted_index.These | 263 |
| abstract_inverted_index.While | 16 |
| abstract_inverted_index.trial | 19 |
| abstract_inverted_index.tumor | 8 |
| abstract_inverted_index.using | 75 |
| abstract_inverted_index.0.001) | 170 |
| abstract_inverted_index.21,698 | 67 |
| abstract_inverted_index.Across | 125 |
| abstract_inverted_index.CANOPY | 29 |
| abstract_inverted_index.CANTOS | 18 |
| abstract_inverted_index.ERBB2, | 238 |
| abstract_inverted_index.IL-1β | 26, 43, 59, 81, 130, 189, 198, 221, 244 |
| abstract_inverted_index.KEAP1, | 239 |
| abstract_inverted_index.NSCLC, | 254 |
| abstract_inverted_index.across | 61 |
| abstract_inverted_index.cancer | 14, 23 |
| abstract_inverted_index.effect | 155 |
| abstract_inverted_index.exact, | 112 |
| abstract_inverted_index.failed | 31 |
| abstract_inverted_index.longer | 137, 204 |
| abstract_inverted_index.lowest | 88 |
| abstract_inverted_index.tests. | 116 |
| abstract_inverted_index.trials | 30 |
| abstract_inverted_index.tumors | 69 |
| abstract_inverted_index.versus | 139 |
| abstract_inverted_index.(median | 143 |
| abstract_inverted_index.0.002). | 183 |
| abstract_inverted_index.0.041), | 216 |
| abstract_inverted_index.benefit | 35 |
| abstract_inverted_index.claims. | 106 |
| abstract_inverted_index.defined | 260 |
| abstract_inverted_index.highest | 91 |
| abstract_inverted_index.models. | 123 |
| abstract_inverted_index.months; | 148, 165, 178, 211 |
| abstract_inverted_index.overall | 94 |
| abstract_inverted_index.reduced | 21 |
| abstract_inverted_index.remains | 49 |
| abstract_inverted_index.studies | 2 |
| abstract_inverted_index.suggest | 3, 265 |
| abstract_inverted_index.tumors. | 277 |
| abstract_inverted_index.without | 186 |
| abstract_inverted_index.(IL-1β) | 6 |
| abstract_inverted_index.(NSCLC). | 15 |
| abstract_inverted_index.0.0001). | 153 |
| abstract_inverted_index.Methods: | 64 |
| abstract_inverted_index.Purpose: | 0 |
| abstract_inverted_index.Results: | 124 |
| abstract_inverted_index.Sciences | 74 |
| abstract_inverted_index.Survival | 117 |
| abstract_inverted_index.analyzed | 66 |
| abstract_inverted_index.assessed | 120 |
| abstract_inverted_index.behavior | 9 |
| abstract_inverted_index.combined | 37 |
| abstract_inverted_index.findings | 264 |
| abstract_inverted_index.modestly | 136, 203 |
| abstract_inverted_index.obtained | 103 |
| abstract_inverted_index.outcomes | 118, 258 |
| abstract_inverted_index.profiled | 70 |
| abstract_inverted_index.relevant | 272 |
| abstract_inverted_index.subsets. | 262 |
| abstract_inverted_index.survival | 34, 95, 257 |
| abstract_inverted_index.unclear. | 50 |
| abstract_inverted_index.TMB-high, | 228 |
| abstract_inverted_index.biomarker | 252 |
| abstract_inverted_index.evaluated | 52 |
| abstract_inverted_index.incidence | 24 |
| abstract_inverted_index.insurance | 105 |
| abstract_inverted_index.inversely | 233 |
| abstract_inverted_index.molecular | 261 |
| abstract_inverted_index.mutation, | 227 |
| abstract_inverted_index.mutations | 48 |
| abstract_inverted_index.non-small | 11 |
| abstract_inverted_index.oncogenic | 47 |
| abstract_inverted_index.patients, | 128 |
| abstract_inverted_index.potential | 248 |
| abstract_inverted_index.quartiles | 86 |
| abstract_inverted_index.subtypes. | 63 |
| abstract_inverted_index.treatment | 100 |
| abstract_inverted_index.Fisher’s | 111 |
| abstract_inverted_index.Real-world | 93 |
| abstract_inverted_index.associated | 134, 201, 255 |
| abstract_inverted_index.correlated | 223 |
| abstract_inverted_index.expression | 60, 82, 131, 141, 190, 199, 222, 231, 245 |
| abstract_inverted_index.influences | 7 |
| abstract_inverted_index.mutations, | 188 |
| abstract_inverted_index.mutations. | 242 |
| abstract_inverted_index.positively | 224 |
| abstract_inverted_index.predictive | 56, 251 |
| abstract_inverted_index.prognostic | 54, 249 |
| abstract_inverted_index.pronounced | 158 |
| abstract_inverted_index.strategies | 268 |
| abstract_inverted_index.stratified | 84 |
| abstract_inverted_index.targetable | 187 |
| abstract_inverted_index.unselected | 126 |
| abstract_inverted_index.ALK-altered | 276 |
| abstract_inverted_index.Chi-square, | 110 |
| abstract_inverted_index.EGFR-mutant | 160 |
| abstract_inverted_index.KRAS-mutant | 195 |
| abstract_inverted_index.Preclinical | 1 |
| abstract_inverted_index.Statistical | 107 |
| abstract_inverted_index.comparisons | 108 |
| abstract_inverted_index.inhibition, | 27 |
| abstract_inverted_index.prognostic. | 193 |
| abstract_inverted_index.sequencing. | 80 |
| abstract_inverted_index.Conclusions: | 243 |
| abstract_inverted_index.demonstrated | 20 |
| abstract_inverted_index.particularly | 271 |
| abstract_inverted_index.significance | 57 |
| abstract_inverted_index.immunotherapy | 207 |
| abstract_inverted_index.Mann–Whitney | 114 |
| abstract_inverted_index.adenocarcinoma | 161 |
| abstract_inverted_index.IL-1β-targeted | 267 |
| abstract_inverted_index.adenocarcinoma, | 196 |
| abstract_inverted_index.fusion-positive | 173 |
| abstract_inverted_index.interleukin-1β | 5 |
| abstract_inverted_index.next-generation | 79 |
| abstract_inverted_index.chemoimmunotherapy. | 39 |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5066525575 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 12 |
| corresponding_institution_ids | https://openalex.org/I26347476 |
| citation_normalized_percentile.value | 0.8866205 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |